Pegzilarginase not checked
Immedica Pharma AB · AEB1102
FollowEvery change as it happens, and a Monday email
Next date
None yet
Trials
0 active
8 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated”In the company’s words, NCT03921541 on ClinicalTrials.gov
- Tested for
- Arginase I Deficiency (3 trials), Hyperargininemia (3 trials), Arginase 1 Deficiency, Small-cell Lung Cancer, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Advanced Cancers
- Main trialPhase 3
- “CAEB1102-300A is a multi-center randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of pegzilarginase in patients with ARG1-D. This study will consist of a screening period; a randomized, double-blind treatment period; a long-term extension; and a follow up visit for final safety assessments.”In the company’s words, NCT03921541 on ClinicalTrials.gov
- Other names
- AEB1102 · Co-ArgI-PEG · Loargys
Other drugs for Arginase I Deficiency
- KRRO-121Korro Bio, Inc. · Phase 1/2
Coming up0
No dates coming up.
Changes1
Last 90 days- 16 NovNew trial: none to Phase 1/2 · ClinicalTrials.gov NCT02488044
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Completed | 1 Feb 2023 | Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency | |
| Phase 3Completed | 17 Jun 2025 | Pegzilarginase in Subjects <24 Months Old With Arginase 1 Deficiency | |
| Phase 2Completed | 15 Dec 2022 | A Study of AEB1102 (Pegzilarginase) in Patients With Arginase 1 Deficiency | |
| Phase 1/2Completed | 28 Feb 2019 | A Phase 1/2 Study of AEB1102 in Patients With Arginase 1 Deficiency | |
| Phase 1/2Terminated | 11 Jun 2020 | Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer | |
| Phase 1Completed | 1 Nov 2017 | A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS | |
| Phase 1Completed | 28 May 2019 | A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors | |
| Phase 3Ended | not given | A Phase 3 Open-Label Study of Safety, Pharmacokinetics and Activity of Weekly Subcutaneous Pegzilarginase in Subjects <24 months old with Arginase 1 Deficiency |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026